Leber Congenital Amaurosis Global Market Report 2025

Description

Leber congenital amaurosis (LCA) is an inherited eye disorder that leads to significant vision impairment or blindness from a young age, caused by genetic mutations that hinder the retina's ability to process light. The condition is marked by weak visual responses, involuntary eye movements (nystagmus), and severe farsightedness due to malfunctioning photoreceptors and gradual retinal degeneration.

Treatment options for LCA primarily include gene therapy, medication, retinal prosthetics, assistive technologies, and other interventions. Gene therapy is a technique that uses genetic material to treat or prevent disorders such as LCA by fixing defective genes. LCA is classified based on the age of onset, including congenital LCA (present at birth), early childhood LCA (1-5 years old), and late-onset LCA (after 6 years). Medications for LCA are distributed through various means such as direct tenders and retail sales, and are used in hospitals, specialized eye clinics, ophthalmology research centers, and home care environments.

The leber congenital amaurosis market research report is one of a series of new reports from The Business Research Company that provides leber congenital amaurosis market statistics, including the leber congenital amaurosis industry global market size, regional shares, competitors with the leber congenital amaurosis market share, detailed leber congenital amaurosis market segments, market trends, and opportunities, and any further data you may need to thrive in the leber congenital amaurosis industry. This leber congenital amaurosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The leber congenital amaurosis market size has grown strongly in recent years. It will grow from $1.01 billion in 2024 to $1.07 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth observed during the historical period can be attributed to factors such as increased awareness of rare eye diseases, greater government funding, enhanced diagnostic methods, the expansion of ophthalmic research centers, and patient advocacy efforts.

The leber congenital amaurosis market size is expected to see strong growth in the next few years. It will grow to $1.34 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period is expected to be driven by higher investments in gene therapy, the rising prevalence of inherited retinal disorders, regulatory approvals for new treatments, the expansion of clinical trials, and an increase in healthcare spending. Key trends for the forecast period include the rise of CRISPR-based therapies, greater collaboration between biotechnology companies, the development of personalized medicine, the growth of teleophthalmology, and advancements in retinal imaging technologies.

The rising prevalence of inherited retinal diseases is expected to drive the growth of the leber congenital amaurosis (LCA) market. Inherited retinal diseases (IRDs) are genetic disorders that affect the retina, the light-sensitive tissue at the back of the eye responsible for vision. The increase in these diseases can be attributed to advancements in genetic testing, greater awareness, better diagnosis, and longer life expectancy. Progress in genetic testing has made it easier to diagnose IRDs, resulting in more cases being identified. Leber congenital amaurosis has helped enhance the understanding of inherited retinal diseases by revealing genetic mutations and disease mechanisms, contributing to the development of targeted therapies and treatments. For example, according to the UK Parliament's House of Commons Library in January 2025, approximately 25,000 people in the UK were affected by inherited retinal diseases in 2024, marking a 2% annual increase. As a result, the growing prevalence of inherited retinal diseases is driving the growth of the leber congenital amaurosis market.

Companies in the leber congenital amaurosis market are increasingly focusing on developing RNA-based treatments to improve vision restoration and disease management. RNA-based therapies utilize RNA molecules to target genetic processes and treat diseases. These therapies include mRNA vaccines, siRNA therapies, antisense oligonucleotides, and RNA aptamers. For instance, in January 2025, Laboratoires Thea S.A.S., a French pharmaceutical company, launched Sepul Bio, a business unit dedicated to advancing RNA therapies for inherited retinal diseases. Sepul Bio is specifically targeting sepofarsen for leber congenital amaurosis 10 (LCA10) and ultevursen for USH2A-associated retinitis pigmentosa. Following the successful dosing of the first patient in the LUNA Phase 2b clinical trial for ultevursen, Sepul Bio is poised to make significant progress in addressing these rare genetic disorders.

In October 2024, Ocuphire Pharma Inc., a US-based biopharmaceutical company, acquired Opus Genetics Inc. for an undisclosed amount. This acquisition aims to create a leading clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases (IRDs). Opus Genetics Inc. is a US-based company that specializes in developing gene therapies for IRDs.

Major players in the leber congenital amaurosis market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Invitae Corporation, Novelion Therapeutics Inc., Andelyn Biosciences Inc., CD Genomics Inc., Editas Medicine Inc., MeiraGTx Holdings plc, Sangamo Therapeutics Inc., LKC Technologies Inc., Aldeyra Therapeutics Inc., Asper Biogene OU, Allergan Inc., ProQR Therapeutics N.V., GenSight Biologics S.A., Ocugen Inc., IVERIC bio Inc. (formerly Ophthotech Corporation), Atsena Therapeutics Inc., HuidaGene Therapeutics Co. Ltd.

North America was the largest region in the leber congenital amaurosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in leber congenital amaurosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the leber congenital amaurosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The leber congenital amaurosis (LCA) market consists of revenues earned by entities by providing services such as clinical trial services, healthcare and patient support services, vision rehabilitation services, and diagnostic testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The leber congenital amaurosis (LCA) market also includes sales of retinal implants, diagnostic testing kits, assistive devices, and gene therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Leber Congenital Amaurosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on leber congenital amaurosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for leber congenital amaurosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The leber congenital amaurosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Treatment Type: Gene Therapy; Pharmaceutical Drugs; Retinal Prosthesis; Assistive Devices; Other Treatments
2) By Age Of Onset: Congenital Leber Congenital Amaurosis (LCA) (From Birth); Early Childhood Leber Congenital Amaurosis (LCA) (1-5 Years); Late-Onset Leber Congenital Amaurosis (LCA) (6 Years And Above)
3) By Distribution Channel:; Direct Tender; Retail Sales
4) By End User: Hospitals; Specialized Eye Clinics; Ophthalmology Research Centers; Home Care Settings; Other End Users
Subsegments:
1) By Gene Therapy: RPE65 Gene Replacement Therapy; CRISPR-Based Gene Editing; AAV (Adeno-Associated Virus) Vector Therapy; Emerging Experimental Gene Therapies
2) By Pharmaceutical Drugs: Retinoid-Based Therapies; Neuroprotective Agents; Anti-Inflammatory Drugs; Antioxidant Therapies
3) By Retinal Prosthesis: Implantable Retinal Chips; Artificial Retinal Stimulation Devices; Bionic Eye Technology
4) By Assistive Devices: Low Vision Aids; Screen Readers and Braille Devices; Mobility Aids for Vision Impairment
5) By Other Treatments: Stem Cell Therapy; Optogenetics-Based Treatments; Visual Rehabilitation Programs; Nutritional and Dietary Interventions
Companies Mentioned: Sanofi S.A.; Novartis AG; Astellas Pharma Inc.; Invitae Corporation; Novelion Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r34597

1. Executive Summary

2. Leber Congenital Amaurosis Market Characteristics

3. Leber Congenital Amaurosis Market Trends And Strategies

4. Leber Congenital Amaurosis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Leber Congenital Amaurosis Growth Analysis And Strategic Analysis Framework

5.1. Global Leber Congenital Amaurosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Leber Congenital Amaurosis Market Growth Rate Analysis
5.4. Global Leber Congenital Amaurosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Leber Congenital Amaurosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Leber Congenital Amaurosis Total Addressable Market (TAM)

6. Leber Congenital Amaurosis Market Segmentation

6.1. Global Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gene Therapy
Pharmaceutical Drugs
Retinal Prosthesis
Assistive Devices
Other Treatments
6.2. Global Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Congenital Leber Congenital Amaurosis (LCA) (From Birth)
Early Childhood Leber Congenital Amaurosis (LCA) (1-5 Years)
Late-Onset Leber Congenital Amaurosis (LCA) (6 Years And Above)
6.3. Global Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Direct Tender
Retail Sales
6.4. Global Leber Congenital Amaurosis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialized Eye Clinics
Ophthalmology Research Centers
Home Care Settings
Other End Users
6.5. Global Leber Congenital Amaurosis Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
RPE65 Gene Replacement Therapy
CRISPR-Based Gene Editing
AAV (Adeno-Associated Virus) Vector Therapy
Emerging Experimental Gene Therapies
6.6. Global Leber Congenital Amaurosis Market, Sub-Segmentation Of Pharmaceutical Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Retinoid-Based Therapies
Neuroprotective Agents
Anti-Inflammatory Drugs
Antioxidant Therapies
6.7. Global Leber Congenital Amaurosis Market, Sub-Segmentation Of Retinal Prosthesis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Implantable Retinal Chips
Artificial Retinal Stimulation Devices
Bionic Eye Technology
6.8. Global Leber Congenital Amaurosis Market, Sub-Segmentation Of Assistive Devices, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Low Vision Aids
Screen Readers and Braille Devices
Mobility Aids for Vision Impairment
6.9. Global Leber Congenital Amaurosis Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Stem Cell Therapy
Optogenetics-Based Treatments
Visual Rehabilitation Programs
Nutritional and Dietary Interventions

7. Leber Congenital Amaurosis Market Regional And Country Analysis

7.1. Global Leber Congenital Amaurosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Leber Congenital Amaurosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Leber Congenital Amaurosis Market

8.1. Asia-Pacific Leber Congenital Amaurosis Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Leber Congenital Amaurosis Market

9.1. China Leber Congenital Amaurosis Market Overview
9.2. China Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Leber Congenital Amaurosis Market

10.1. India Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Leber Congenital Amaurosis Market

11.1. Japan Leber Congenital Amaurosis Market Overview
11.2. Japan Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Leber Congenital Amaurosis Market

12.1. Australia Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Leber Congenital Amaurosis Market

13.1. Indonesia Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Leber Congenital Amaurosis Market

14.1. South Korea Leber Congenital Amaurosis Market Overview
14.2. South Korea Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Leber Congenital Amaurosis Market

15.1. Western Europe Leber Congenital Amaurosis Market Overview
15.2. Western Europe Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Leber Congenital Amaurosis Market

16.1. UK Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Leber Congenital Amaurosis Market

17.1. Germany Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Leber Congenital Amaurosis Market

18.1. France Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Leber Congenital Amaurosis Market

19.1. Italy Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Leber Congenital Amaurosis Market

20.1. Spain Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Leber Congenital Amaurosis Market

21.1. Eastern Europe Leber Congenital Amaurosis Market Overview
21.2. Eastern Europe Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Leber Congenital Amaurosis Market

22.1. Russia Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Leber Congenital Amaurosis Market

23.1. North America Leber Congenital Amaurosis Market Overview
23.2. North America Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Leber Congenital Amaurosis Market

24.1. USA Leber Congenital Amaurosis Market Overview
24.2. USA Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Leber Congenital Amaurosis Market

25.1. Canada Leber Congenital Amaurosis Market Overview
25.2. Canada Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Leber Congenital Amaurosis Market

26.1. South America Leber Congenital Amaurosis Market Overview
26.2. South America Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Leber Congenital Amaurosis Market

27.1. Brazil Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Leber Congenital Amaurosis Market

28.1. Middle East Leber Congenital Amaurosis Market Overview
28.2. Middle East Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Leber Congenital Amaurosis Market

29.1. Africa Leber Congenital Amaurosis Market Overview
29.2. Africa Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Leber Congenital Amaurosis Market Competitive Landscape And Company Profiles

30.1. Leber Congenital Amaurosis Market Competitive Landscape
30.2. Leber Congenital Amaurosis Market Company Profiles
- 30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Invitae Corporation Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novelion Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Leber Congenital Amaurosis Market Other Major And Innovative Companies

31.1. Andelyn Biosciences Inc.
31.2. CD Genomics Inc.
31.3. Editas Medicine Inc.
31.4. MeiraGTx Holdings plc
31.5. Sangamo Therapeutics Inc.
31.6. LKC Technologies Inc.
31.7. Aldeyra Therapeutics Inc.
31.8. Asper Biogene OU
31.9. Allergan Inc.
31.10. ProQR Therapeutics N.V.
31.11. GenSight Biologics S.A.
31.12. Ocugen Inc.
31.13. IVERIC bio Inc. (formerly Ophthotech Corporation)
31.14. Atsena Therapeutics Inc.
31.15. HuidaGene Therapeutics Co. Ltd.

32. Global Leber Congenital Amaurosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Leber Congenital Amaurosis Market

34. Recent Developments In The Leber Congenital Amaurosis Market

35. Leber Congenital Amaurosis Market High Potential Countries, Segments and Strategies

35.1 Leber Congenital Amaurosis Market In 2029 - Countries Offering Most New Opportunities
35.2 Leber Congenital Amaurosis Market In 2029 - Segments Offering Most New Opportunities
35.3 Leber Congenital Amaurosis Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer